600062 China Resources Double-Crane Pharmaceutical
- 21.61
- -0.04-0.18%
About China Resources Double-Crane Pharmaceutical Company
The company has a glorious history of 84 years. It was founded in 1939. It was originally founded in the Taihang Mountain Revolutionary Base, known as Lihua Pharmaceutical Factory; moved to Beijing with the army in 1949, later changed its name to Beijing Pharmaceutical Factory, and developed into a large-scale state-owned chemical drug comprehensive formulation enterprise, laying the foundation for Beijing's modern chemical pharmaceutical industry; in 1997, it integrated high-quality assets to establish Shuanghe Pharmaceutical and was listed on the Shanghai Stock Exchange. Through epitaxial expansion, it became a cross-regional group based in Beijing and covering the whole country; in 2010, it joined the Fortune 500 enterprise China Resources Group, and now renamed China Resources Shuanghe Group in 2012. Big for China Resources Group One of the business units in the health sector. The company's formulation business is deeply involved in chronic disease business, specialty business and infusion business. The company's main products include compound reserpine tripteridine tablets (No. 0), amlodipine benzenesulfonate tablets (diazepam), gliquinone tablets (glucosepine), citin choline sodium tablets (norbiol), magnesium valproate sustained-release tablets (Shintec), pentazocine, lidocaine, parecoxib sodium, encapsulated polypropylene infusion (BFS), etc. Corporate honors: “Beijing Municipal People's Government Quality Management Award”, “High-tech Enterprise”, “China's Top 100 Chemical and Pharmaceutical Industry Enterprises with Comprehensive Strength”, “Top 100 Chinese Pharmaceutical Enterprises” and many other honors.
Company Profile
Company Executives
- Name
- Position
- Salary
- wenchao lu
- Chairman, Directors, Chairman of the Strategy Committee
- 2.32M
- shutian yu
- Directors, Audit and Risk Management Committee Member
- --
- hui xu
- Directors, Nomination and Corporate Governance Committee Member
- --
- xiangming li
- Directors, Strategy Committee Members
- --
- guolong lin
- Directors, Audit and Risk Management Committee Member
- --
- xiaosong bai
- Directors, Strategy Committee Members
- --
- qian zhao
- Directors, President, Member of the Remuneration and Assessment Committee
- --
- shunkun yu
- Independent Directors, Chairman of the Remuneration and Assessment Committee, Strategy Committee Members
- --
- ning liu
- Independent Directors, Chairman of the Nomination and Corporate Governance Committee, Audit and Risk Management Committee Member
- 150.00K
- maozhu sun
- Independent Directors, Chairman of the Audit and Risk Management Committee, Member of the Remuneration and Assessment Committee
- 150.00K
- zhen chen
- Independent Directors, Nomination and Corporate Governance Committee Member, Audit and Risk Management Committee Member, Strategy Committee Members
- --
- ju liu
- Board Secretary, Chief Financial Officer
- --
- lihong zheng
- Securities Affairs Representative
- --
- jianguo liu
- Chairman of the Supervisory Board, Auditors
- --
- jiao zhou
- Auditors
- --
- wei zhang
- Auditors
- --
- ziqin liu
- VP
- 1.60M
- chengjin wu
- VP
- 1.42M
- donghan yao
- Deputy General Manager
- 923.00K
- chao man
- VP
- 1.80M
- hekai tan
- VP
- 1.11M
- yuan jiang
- Head of Audit Department, Employee Supervisors
- --
- jie wang
- Employee Supervisors
- --
Analysis
Price Target
No Data
No Data